Innovenn starts production of Labskin skin substitute at new UK facility
Based on the Innovation Campus at Sand Hutton, North Yorkshire
Innovenn, the innovation division of Venn Life Sciences, a clinical research organisation (CRO) based in Dublin, Ireland, has started production of its pioneering product Labskin at its new state of the art laboratory facilities on the Innovation Campus at Sand Hutton, North Yorkshire, UK.
Labskin, a human skin equivalent, allows high quality skin research to be carried out in the sponsor's own facilities. Unlike most skin models, Labskin provides an environment similar to human skin in that it can house microflora.
Innovenn said starting production at these new facilities marks a milestone for the company as it streamlines operations to deal with larger order volumes and a wider geographic distribution.
The company has also recently recruited additional technical staff to assist with production and order fulfilment.
Tony Richardson, CEO of Venn Life Sciences said: 'We are delighted to be able to offer our clients one of the most exciting skin research products ahead of schedule from our facilities in York. We will continue to work and build capacity in order to increase our worldwide distribution of Labskin and the provision of associated microbiology services.'
